Phase Forward Signs Multi-Year Agreement with Major Pharmaceutical Company Gedeon Richter
Waltham, MA
Phase Forward announced a multi-year agreement with Gedeon Richter Plc., a leading pharmaceutical company in Central-Eastern Europe. Gedeon Richter plans to adopt Phase Forward’s Clintrial™ product for its clinical trial data management activities.
Founded in 1901 and headquartered in Budapest, Hungary, Gedeon Richter’s organization manufactures and markets generic pharmaceutical products for the treatment of a variety of therapy areas including gynecology and cardiology. After completing a competitive product review, Gedeon Richter selected Phase Forward.
“We know that we are collaborating with the premier technology provider for clinical trials – and we look forward to garnering the benefits inherent in greater drug trial efficiencies,” said György Németh, medical director, Gedeon Richter.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
